|
PDIA6 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.0382363291892E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.17739945465689E-10 |
| Normal-vs-Stage2 |
3.021900E-04 |
| Normal-vs-Stage3 |
9.6034291630076E-14 |
| Normal-vs-Stage4 |
7.19480031108333E-12 |
| Stage1-vs-Stage2 |
2.085200E-01 |
| Stage1-vs-Stage3 |
6.656400E-03 |
| Stage1-vs-Stage4 |
9.636400E-03 |
| Stage2-vs-Stage3 |
3.517300E-03 |
| Stage2-vs-Stage4 |
3.677400E-03 |
| Stage3-vs-Stage4 |
6.108800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.44089209850063E-15 |
| Normal-vs-AfricanAmerican |
8.002000E-04 |
| Normal-vs-Asian |
4.13070022631246E-10 |
| Caucasian-vs-AfricanAmerican |
3.166000E-01 |
| Caucasian-vs-Asian |
9.052800E-01 |
| AfricanAmerican-vs-Asian |
3.677800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.68139979506554E-11 |
| Normal-vs-Female |
1.32499566873889E-11 |
| Male-vs-Female |
6.649800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.26120003329788E-10 |
| Normal-vs-Age(41-60Yrs) |
1.55520041289492E-11 |
| Normal-vs-Age(61-80Yrs) |
4.0955000502052E-09 |
| Normal-vs-Age(81-100Yrs) |
1.153440E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.203000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.202600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.688200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.628200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.376200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.087800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.68847183299204E-13 |
| Classical-VS-Follicular |
5.99169999999649E-05 |
| Classical-VS-Other |
3.464200E-01 |
| Classical-VS-Normal |
1.62481139653892E-12 |
| Tall-VS-Follicular |
4.11892742135933E-14 |
| Tall-VS-Other |
1.990990E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
6.010100E-02 |
| Follicular-VS-Normal |
1.011800E-02 |
| Other-VS-Normal |
8.4409000000063E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.02239999969045E-07 |
| Normal-vs-N1 |
3.33066907387547E-15 |
| N0-vs-N1 |
3.59500000002289E-06 |
|
|
